Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2026 09:00 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of NuScale Power Corporation Investors

LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NuScale Power Corporation, (“NuScale” or the "Company") (NYSE: SMR) investors off a class action on behalf of investors...
March 11, 2026 09:07 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...
March 11, 2026 08:00 ET | Source: Biogen Inc.

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene...
March 10, 2026 09:15 ET | Source: USA News Group

The Race for Uranium Has Gone Global

VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- USANewsgroup.com News Commentary — The United States currently imports roughly 95% of the uranium it consumes, leaving the world’s...
March 09, 2026 16:30 ET | Source: Mesa Laboratories, Inc.

Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO

LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and...
March 09, 2026 07:00 ET | Source: Relmada Therapeutics

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time...
March 09, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins,...
March 08, 2026 16:11 ET | Source: Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against NuScale Power Corporation, Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

The case alleges that NuScale failed to disclose that it entrusted its NPM commercialization to an entity that lacked significant prior experience.
March 06, 2026 08:45 ET | Source: F. Hoffmann-La Roche Ltd

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the...
March 05, 2026 16:21 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia...